세계의 G단백질 결합 수용체 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The G-protein coupled receptors market size stands at USD 4.52 billion in 2025 and is forecast to reach USD 6.41 billion by 2030, expanding at a 7.24% CAGR as artificial-intelligence tools replace legacy radioligand screens in early discovery workflows.

Increasing adoption of structure-guided design based on AlphaFold2 models is broadening the addressable receptor universe, while oral small-molecule GLP-1 programs sustain venture funding momentum and catalyze new partnership structures. North American sponsors continue to dominate filings, yet Asia Pacific laboratories are scaling fastest as governments align review standards and subsidize translational infrastructure. Oncology keeps the largest therapeutic footprint, but cardiovascular projects post the sharpest acceleration on the back of allosteric discovery breakthroughs. Overall, the G-protein coupled receptors market is benefiting from modular platform innovation, moderated competitive intensity and a widening pool of first-in-class targets.

Global G-Protein Coupled Receptors (GPCR) Market Trends and Insights

Surging Adoption of HTS Platforms for GPCR Assays

High-throughput screening instruments are replacing manual radioligand methods as sponsors demand faster, label-free read-outs that eliminate isotope handling. Bioluminescence resonance energy transfer sensors further improve sensitivity by capturing conformational shifts in real time, and impedance-based microelectrode arrays provide a non-invasive proxy for electrophysiological responses with 0.85 correlation to patch-clamp data. Vendor roadmaps integrate robotics for micro-volume dispensing and cloud analytics that rank ligand hits automatically. Together, these advances reinforce the G-protein coupled receptors market as a fertile ground for precision pharmacology projects.

Growing Drug-Discovery Spend Targeting GPCRs

G protein-coupled receptors (GPCRs) underpin 36% of approved medicines, yet three-quarters of receptor subtypes still lack marketed drugs, prompting sustained R&D allocations. Diabetes and obesity agents alone delivered nearly USD 30 billion in 2024 sales, validating the commercial upside and steering budgets toward oral small-molecule GLP-1, amylin and dual-agonist candidates. Structure Therapeutics illustrates the scale, carrying USD 883.5 million in cash earmarked for Phase 2b GLP-1 and GIPR programs. Licensing deals echo investor confidence, with Novo Nordisk's collaboration with Septerna valued at up to USD 2.2 billion for oral obesity pills. Such capital flows underpin the near-term pipeline and solidify the G-protein coupled receptors market as a strategic priority for big pharma.

Purification & Stability Challenges of GPCRs

Membrane proteins lose native conformation once removed from lipid bilayers, complicating crystallography and biophysical assays. Detergent solubilization often strips stabilizing lipids, prompting adoption of styrene-maleic-acid copolymers that preserve native nanodiscs. Recent innovations attach Ga-mimetic peptides to chromatography resin, enabling tag-free isolation of active receptors at preparative scale. Nevertheless, each GPCR subtype demands bespoke thermostabilization cycles, delaying platform standardization and tempering near-term efficiency gains in the G-protein coupled receptors market.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Burden of Chronic & Metabolic Diseases
2. Expansion of Biologics & Allosteric Modulators
3. Signal-Bias Complexity Hampers Assay Design

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and kits provided the backbone of GPCR discovery workflows and represented 36.44% of G-protein coupled receptors market share in 2024, reflecting universal demand for buffers, ligands and detection chemistries. Automated liquid handlers, photonic readers and impedance modules constitute the platform category, which is climbing at an 8.92% CAGR thanks to miniaturization and cloud-linked analytics. The convergence of AI algorithms with optical sensors now supports end-to-end hit triaging inside a single workstation, accelerating time-to-lead and widening access for mid-tier firms.

Service contracts are expanding as drug sponsors outsource high-content screens to CROs that maintain proprietary cell banks and assay libraries. Eurofins CEREP, for example, couples 20 years of receptor pharmacology know-how with high-density screening lines to shorten client program timelines. Hybrid offerings bundle reagents, plates and analytics licences under subscription models, allowing labs to align capital outlay with project milestones. Consequently, platforms and service ecosystems anchor the value shift within the G-protein coupled receptors market.

Intracellular calcium mobilization kits led revenues at 28.71% in 2024, mirroring their historic role in class-A receptor programs. Yet cAMP detection formats are projected to register a 9.01% CAGR, underpinned by NanoLuc binary technologies that quantify cyclic-AMP in live cells with sub-nanomolar sensitivity. Radioligand and GTPYS methods endure for orthogonal confirmation, although regulatory pressure on radioisotope waste curbs broader uptake.

B-arrestin biosensors continue to gain currency for pathways implicated in cardiometabolic safety profiling, and label-free impedance plates now record morphological changes without fluorescent tags. ThermoBRET protocols further streamline thermostability assessments by eliminating labelled ligands, trimming consumable costs during lead optimization. Collectively, these technologies extend the functional repertoire available to the G-protein coupled receptors market.

The G-Protein Coupled Receptors Market Report is Segmented by Component(Reagents & Kits and More), Assay Type (Calcium Level Detection Assays and More), Therapeutic Area (Cardiovascular System and More), End-User (Pharmaceutical & Biotech Companies and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America commanded 37.43% of 2024 sales as Boston, San Francisco and San Diego clusters combined venture capital, AI talent and FDA guidance that clarifies machine-learning evidence packages. Domestic incumbents release iterative instrumentation upgrades annually, enabling users to retrofit established laboratories without disruptive capital cycles. Long-standing NIH funding streams for structural biology further solidify the region's dominance within the G-protein coupled receptors market.

Europe contributes a balanced mix of academic excellence and regulatory pragmatism. EMA endorsements of Winrevair for pulmonary arterial hypertension and Obgemsa for overactive bladder verified the approval pathway for novel GPCR therapies in 2024. Continental institutes such as the University of Basel are pushing envelope techniques like GPS-NMR to trace receptor motions at atomic resolution, insights that feed directly into ligand engineering cycles. Combined, these factors nurture a robust albeit steady growth profile across the European slice of the G-protein coupled receptors market.

Asia-Pacific, projected at an 8.85% CAGR through 2030, benefits from concerted governmental drives to bolster biotech self-reliance and harmonize approval timelines. Japan's discovery of intracellular-side activators such as PCO371 exemplifies the region's ingenuity, promising orally available agents with reduced systemic side-effects. China and South Korea are expanding manufacturing capacity for peptide therapeutics, while venture funds co-invest with multinationals to accelerate regional trial sites. Emerging economies in Latin America, the Middle East and Africa remain smaller but are ramping clinical infrastructure via technology-transfer agreements, positioning themselves as future contributors to the G-protein coupled receptors market.

1. Abcam
2. Addex Therapeutics
3. Beckton Dickinson
4. BioInvenu
5. Bio-Rad Laboratories
6. BMG Labtech GmbH
7. Charles River
8. Cisbio
9. Corning
10. Danaher
11. Enzo Biochem
12. Eurofins Scientific SE (DiscoverX)
13. Evotec
14. HD Biosciences
15. ION Biosciences
16. Luminex
17. Merck
18. Promega
19. Reaction Biology Corp.
20. Revvity Inc
21. Structure Therapeutics Inc.
22. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Surging adoption of HTS platforms for GPCR assays
  • 4.2.2 Growing drug-discovery spend targeting GPCRs
  • 4.2.3 Rising burden of chronic & metabolic diseases
  • 4.2.4 Expansion of biologics & allosteric modulators
  • 4.2.5 AI-enabled structure-guided GPCR modeling
  • 4.2.6 VC boom in oral small-molecule GLP-1 agonists
• 4.3 Market Restraints
  • 4.3.1 Purification & stability challenges of GPCRs
  • 4.3.2 Signal-bias complexity hampers assay design
  • 4.3.3 High cost of advanced assay platforms
  • 4.3.4 IP clustering limits freedom-to-operate
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Component
  • 5.1.1 Reagents & Kits
  • 5.1.2 Cell Lines
  • 5.1.3 Assay Platforms
  • 5.1.4 Detection Instruments
  • 5.1.5 Services
• 5.2 By Assay Type
  • 5.2.1 Calcium Level Detection Assays
  • 5.2.2 Radioligand Binding & GTP?S Assays
  • 5.2.3 cAMP & cGMP Assays
  • 5.2.4 B-Arrestin Functional Assays
  • 5.2.5 Reporter Gene Assays
  • 5.2.6 Label-free Impedance Assays
  • 5.2.7 Other Assay Types
• 5.3 By Therapeutic Area
  • 5.3.1 Cardiovascular System
  • 5.3.2 Central Nervous System
  • 5.3.3 Oncology
  • 5.3.4 Metabolic Disorders
  • 5.3.5 Respiratory Diseases
  • 5.3.6 Other Therapeutic Areas
• 5.4 By End-User
  • 5.4.1 Pharmaceutical & Biotech Companies
  • 5.4.2 Contract Research Organizations (CROs)
  • 5.4.3 Academic & Research Institutes
  • 5.4.4 Diagnostic Laboratories
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Competitive Benchmarking
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Abcam plc
  • 6.4.2 Addex Therapeutics Ltd.
  • 6.4.3 Becton, Dickinson and Company
  • 6.4.4 BioInvenu Inc.
  • 6.4.5 Bio-Rad Laboratories Inc.
  • 6.4.6 BMG Labtech GmbH
  • 6.4.7 Charles River Laboratories
  • 6.4.8 Cisbio
  • 6.4.9 Corning Incorporated
  • 6.4.10 Danaher Corporation
  • 6.4.11 Enzo Biochem Inc.
  • 6.4.12 Eurofins Scientific SE (DiscoverX)
  • 6.4.13 Evotec SE
  • 6.4.14 HD Biosciences Co., Ltd.
  • 6.4.15 ION Biosciences
  • 6.4.16 Luminex Corporation
  • 6.4.17 Merck KGaA
  • 6.4.18 Promega Corporation
  • 6.4.19 Reaction Biology Corp.
  • 6.4.20 Revvity Inc
  • 6.4.21 Structure Therapeutics Inc.
  • 6.4.22 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment